TapImmune Inc. Share Price Other OTC
Equities
US8760333091
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
15/05 | Earnings Flash (MRKR) MARKER THERAPEUTICS Reports Q1 Revenue $1.2M | MT |
15/05 | Marker Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 3.09Cr 258.66Cr |
---|---|---|---|---|---|
Net income 2024 * | -1.7Cr -142.08Cr | Net income 2025 * | -3.1Cr -259.09Cr | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-2.71
x | P/E ratio 2025 * |
-2.71
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 87.8% |
Latest transcript on TapImmune Inc.
Managers | Title | Age | Since |
---|---|---|---|
Juan Vera
CEO | Chief Executive Officer | 44 | 17/18/17 |
Monic Stuart
CTO | Chief Tech/Sci/R&D Officer | - | - |
Gerald Garrett
CTO | Chief Tech/Sci/R&D Officer | 59 | 01/19/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Norman Eansor
CHM | Chairman | 63 | 17/18/17 |
Steven Elms
BRD | Director/Board Member | 60 | 06/19/06 |
Katharine Knobil
BRD | Director/Board Member | 60 | 08/21/08 |
1st Jan change | Capi. | |
---|---|---|
+48.76% | 5.69TCr | |
+39.98% | 4.03TCr | |
-7.21% | 3.93TCr | |
-4.42% | 2.84TCr | |
+12.35% | 2.64TCr | |
-17.98% | 1.94TCr | |
+29.54% | 1.25TCr | |
+26.02% | 1.22TCr | |
-0.66% | 1.21TCr |